IRIX - IRIDEX Corporation Trailing Twelve Months Revenue Growth

The rolling 12-month sales growth rate year-over-year reflects the impact of external procurement of optics and boards, with the value recorded at 3.70. IRIDEX Corporation (IRIX) maintains revenue stability through long-term loyalty from clinics utilizing proprietary consumables. Business development relies on expanding the distribution network and partnering with ophthalmology centers without engaging in merger and acquisition transactions.
IRIDEX Corp (IRIX) - metric breakdowns and financial figures

IRIDEX Corporation dominates the ophthalmological laser equipment segment thanks to unique patents. By analyzing the trailing twelve-month (TTM) sales growth rate, an investor can see the real revenue scaling dynamics over the last twelve months. This metric strips out one-time adjustments, revealing the true intensity of expansion within the B2B sector. For IRIDEX Corporation, this reflects the penetration rate of glaucoma treatment systems into clinics. A stable upward trend confirms the fundamental resilience of the business model.